Bristol Myers cell therapy manufacturing site gets thumbs-up from FDA

A new Bris­tol My­ers Squibb cell man­u­fac­tur­ing site that is ex­pect­ed to make the CAR-T ther­a­py Breyanzi has re­ceived FDA ap­proval to start pro­duc­tion.

The phar­ma an­nounced that its 244,000-square-foot cell ther­a­py man­u­fac­tur­ing site in De­vens, MA, has got­ten a OK from the FDA to be­gin com­mer­cial pro­duc­tion. The man­u­fac­tur­ing fa­cil­i­ty is the lat­est ex­pan­sion at the BMS cam­pus there, which al­ready has de­vel­op­ing, test­ing and man­u­fac­tur­ing ca­pa­bil­i­ties for BMS med­i­cines. The fa­cil­i­ty is ex­pect­ed to em­ploy 500 work­ers.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN